Sonic Healthcare Ltd
ASX:SHL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.6), the stock would be worth AU$27.59 (37% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.2 | AU$20.18 |
0%
|
| 3-Year Average | 1.6 | AU$27.59 |
+37%
|
| 5-Year Average | 1.9 | AU$32.57 |
+61%
|
| Industry Average | 3.3 | AU$55.26 |
+174%
|
| Country Average | 2.7 | AU$45.3 |
+124%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
10B AUD | 1.2 | 18.9 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
102.9B USD | 1.4 | 58.2 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
70.3B EUR | 1.9 | 13.6 | |
| US |
|
Cigna Corp
NYSE:CI
|
75.1B USD | 1.8 | 12.6 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.6B EUR | 1.7 | 23.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23B EUR | 1.2 | 18.2 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.7B USD | 2.9 | 21.2 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.3B USD | 2.5 | 24.3 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.8 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | -109.3 | -26.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | -15.8 | 13.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.3 |
| Max | 2 199.4 |
Other Multiples
Sonic Healthcare Ltd
Glance View
Sonic Healthcare Ltd. began its journey in 1987, carved from a niche of independent pathology practices in Australia. It swiftly evolved into a global player, embracing a model that combines local expertise with the strength of an international network. The heart of Sonic's operations lies in its robust diagnostic services. Its laboratories process millions of tests each year, ensuring timely and accurate results across a spectrum of medical diagnostics, including pathology, radiology, and general practice medicine. This core service is augmented by state-of-the-art technology and a commitment to quality care, which has earned Sonic a reputation for reliability and excellence in the healthcare sector. Financially, Sonic Healthcare thrives on a business model that capitalizes on high volume and steady demand for medical diagnostic services. The company generates revenue through contracts with hospitals, clinics, and governments, providing essential health services that are non-discretionary and resilient, even in economic downturns. Growth is driven by strategic acquisitions and partnerships, which expand its footprint across regions like North America and Europe, ensuring a stream of diversified income. As healthcare spending continues to rise globally, Sonic Healthcare's business model remains well-positioned to leverage its international presence and expertise in diagnostic excellence, fueling sustainable growth and shareholder value over the long term.
